Articles tagged "HLA antibodies"

2017 American Transplant Congress
Development of an Anti-HLA Antibody-Producing Humanized Mouse Model.
S. Yanagawa, H. Tahara, H. Ohdan.
Hiroshima University, Hiroshima, Japan; Hiroshima University, Hiroshima, Japan; Hiroshima University, Hiroshima, Japan
Chronic antibody-mediated rejection due to anti-human leukocyte antigen (HLA) antibodies (Abs) is an important problem in organ transplantation. The spleen has been reported to be…
2017 American Transplant Congress
Predicting Immunologic Risk for Acute Rejection in Pediatric Liver Transplantation.
S. Antala, L. Bow, R. Morotti, G. Gan, D. Yanhong, U. Ekong, S. Emre.
Yale University, New Haven, CT
Background: Studies in heart, lung, kidney, & liver transplantation (LT) indicate an increased negative impact of antibodies (Ab) to HLA on allograft outcome.Aim: To describe…
2017 American Transplant Congress
Clinical Outcomes of ABO and HLA Incompatible Kidney Transplantation – Nationwide Cohort Study.
E. Ko,^1,2 J. Yu,^1,2 C. Yang,^1,2 B. Chung,^1,2 Korean Organ Transplantation Registry (KOTRY).
¹Transplantation Research Center, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea; ²Division of Nephrology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
Background This is a nationwide cohort study to investigate the impact of anti-A/B antibody or donor specific anti-HLA antibody (HLA-DSA) on the clinical outcomes in…
2017 American Transplant Congress
C3d Assay Result in Potential Transplant Recipients with HLA-DSA, AHG-CDC CxM Negative and FxM Positive or Negative with Their Potential Donors.
A. Contreras, A. Casillas, N. Castelan, N. Gonzalez-Tableros, M. Lopez, A. Arvizu, A. De Santiago, J. Alberu, J. Arreola-Guerra.
Transplantation Department, Instituto Nacional de Ciencias Medicas y Nutricion SZ, Mexico City, Mexico
Background: In a previous study we searched the association between the flow cytometry cross-match assay (FXM) result and the results obtained in the analysis of…
2017 American Transplant Congress
Correlation of Complement Activating Donor Specific Antibodies as Measured by C3d and Cross-Match Status.
A. Babu,^1,2,3 N. Krishnan,² D. Briggs,³ D. Mitchell,¹ S. Daga.^1,2,4
¹Warwick Medical School, University of Warwick, Coventry, United Kingdom; ²Nephrology and Transplantation, University Hospitals Coventrya and Warwickshire, Coventry, United Kingdom; ³Histocompatibility and Immunogenetics, NHS Blood and Transfusion, Birmingham, United Kingdom; ⁴Nephrology and Transplantation, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Introduction. Complement dependent cytotoxicity, first described in 1969 is the only functional assay studying complement activation. C3d assay is developed recently to study complement activation…
2016 American Transplant Congress
A Virtual Crossmatch Algorithm That Mimics the Sensitivity of Flow Cytometric Crossmatch.
P. Rao, D. Deo, C. Rhodes, D. King, P. Bowe, J. Napoleon, I. Okere.
NJ Sharing Network, New Providence, NJ.
Aim: The new Kidney Allocation System has increased requests for virtual crossmatches (VXM) to predict the possibility of a negative donor specific crossmatch. This study…
2016 American Transplant Congress
Long-Term Follow-Up of Renal Transplant Recipients (RTR) Treated with IVIG for De Novo Donor Specific Antibodies (DSA).
R. Knight,¹ S. Patel,¹ J. Loucks-DeVos,² S. Kuten,¹ A. Gaber.¹
¹Houston Methodist Hospital, Houston, TX; ²Kansas University Medical Center, Kansas City, KS.
Intravenous immune globulin (IVIG) may be beneﬁcial for pre-emptive treatment of de novo DSA in RTR without biopsy-proven acute rejection (AR). Herein, we present long-term…
2016 American Transplant Congress
Impact of Early Red Blood Cell Transfusion After Kidney Transplantation on De Novo HLA Sensitization in the Setting of Antithymocyte Globulin Induction.
T. Jouve,^1,2 G. Rigault,^1,2 B. Janbon,¹ R. Tetaz,¹ N. Terrier,¹ D. Masson,³ L. Rostaing,^1,2 P. Malvezzi.¹
¹Nephrology and Kidney Transplantation Unit, Grenoble University Hospital, Grenoble, France, Metropolitan; ²Grenoble Alpes University, Grenoble, France, Metropolitan; ³Etablissement Francais du Sang, Grenoble, France, Metropolitan.
Introduction:HLA specific antibodies detection (HSA) and that of Donor Specific Antibodies (DSA) were revolutionized by the introduction of solid phase assays (Luminex®), therefore making these…
2016 American Transplant Congress
Kidney Transplantation with Strong Preformed Donor-Specific Antibodies: Impact of C1q-Binding Ability.
J. Malheiro,¹ S. Tafulo,² S. Santos,¹ M. Costa,¹ L. Martins,¹ L. Dias,¹ A. Henriques.¹
¹Nephrology, CHP, Porto, Portugal; ²CSTP, Porto, Portugal.
HLA-incompatible kidney transplantation is associated with worse outcomes given the presence of donor-specific anti-HLA antibodies (DSA). Our aim was to investigate the association between preformed…
2016 American Transplant Congress
Impact of the New Kidney Allocation System (KAS) on Transplant Rates & Outcomes in Broadly-HLA Sensitized (HS) Patients Transplanted After Desensitization (DES).
A. Vo,¹ X. Zhang,² S. Williamson,¹ K. Myers,¹ N. Reinsmoen,² J. Choi,¹ J. Kahwaji,¹ A. Peng,¹ R. Villicana,¹ S. Jordan.¹
¹Kidney Transplant, Cedars-Sinai Medical Center, LA, CA; ²HLA Laboratory, Cedars-Sinai Medical Center, LA, CA.
Introduction: HS patients not desensitized (DES) receiving transplants are at risk for ABMR. DES improves transplant rates, but is limited to donor availability. Implementation of…